Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Moore

Showing results (641-650 of 649) with videos related to

Pageof 65
Sort By:
You have reached the last page of results.This site can display upto 649 results.
Microbial Genomics|May 8, 2024
Defining the phylogenetics and resistome of the major <i>Clostridioides difficile</i> ribotypes circulating in AustraliaKeeley O'Grady, Stacey Hong, Papanin Putsathit, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Substituted 2-aminopyridines as inhibitors of nitric oxide synthasesW K Hagmann, C G Caldwell, P Chen, et al.
Bioscience|October 7, 2021
Blue Waters, Green Bottoms: Benthic Filamentous Algal Blooms Are an Emerging Threat to Clear Lakes WorldwideYvonne Vadeboncoeur, Marianne V Moore, Simon D Stewart, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
The AAPS Journal|April 5, 2015
Advancing Product Quality: a Summary of the Inaugural FDA/PQRI ConferenceLawrence X Yu, Jeffrey Baker, Susan C Berlam, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 65

Showing results (641-650 of 649) with videos related to

Sort By:
Pageof 65
You have reached the last page of results.This site can display upto 649 results.
Microbial Genomics|May 8, 2024
Defining the phylogenetics and resistome of the major <i>Clostridioides difficile</i> ribotypes circulating in AustraliaKeeley O'Grady, Stacey Hong, Papanin Putsathit, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Substituted 2-aminopyridines as inhibitors of nitric oxide synthasesW K Hagmann, C G Caldwell, P Chen, et al.
Bioscience|October 7, 2021
Blue Waters, Green Bottoms: Benthic Filamentous Algal Blooms Are an Emerging Threat to Clear Lakes WorldwideYvonne Vadeboncoeur, Marianne V Moore, Simon D Stewart, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
The AAPS Journal|April 5, 2015
Advancing Product Quality: a Summary of the Inaugural FDA/PQRI ConferenceLawrence X Yu, Jeffrey Baker, Susan C Berlam, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 65